Manijeh Beigi | Medical Physics | Best Researcher Award

Posted on by sciencefather

Dr. Manijeh Beigi | Medical Physics | Best Researcher Award

Dr. Manijeh Beigi is an Assistant Professor in the Radiation Oncology Department at Iran University of Medical Sciences. She specializes in dosimetry, radiotherapy treatment planning, and quality audits, with a focus on using machine learning for radiomics and dosiomics analysis. Dr. Beigi earned her Ph.D. in Medical Physics from Tehran University of Medical Sciences in 2018, where she researched the application of Diffusion Tensor Imaging (DTI) in radiotherapy planning. With over a decade of experience in radiotherapy physics, she has worked in multiple hospitals, including Imam Hosein, Haft-e-Tir, and Pardis Niloo Cancer Center. She is actively involved in research on predicting radiotherapy toxicity and advanced MR imaging applications. Dr. Beigi has mentored numerous students, contributed to high-impact journals, and presented at international conferences. Her research aims to enhance radiotherapy precision and patient safety through cutting-edge imaging and AI-driven models. 🎓🔬

Profile

Education 🎓

Dr. Manijeh Beigi holds a Ph.D. in Medical Physics (2018) from Tehran University of Medical Sciences, where she developed automated clinical target volume determination for glioma treatment using multiparametric MRI. She completed her M.Sc. in Medical Physics (2010) at Tarbiat Modares University, focusing on radiotherapy dosimetry and quality audits in Varian linear accelerators. Her coursework covered key topics such as radiotherapy physics, radiobiology, MRI, CT, and PET physics, statistical methods, and treatment planning. Throughout her academic journey, she has specialized in advanced imaging techniques, radiomics, and AI-based predictive modeling for radiotherapy applications. Dr. Beigi’s education has provided her with strong expertise in medical physics, treatment planning optimization, and quality assurance, positioning her as a leader in radiation oncology research and innovation. 📚

Experience 👨‍🏫

Dr. Manijeh Beigi has been an Assistant Professor at Iran University of Medical Sciences since 2020, where she focuses on radiotherapy physics, treatment planning, and quality assurance. Previously, she worked as a Radiotherapy Physicist at Imam Hosein Hospital (2010-2016), Haft-e-Tir Hospital (2016-Present), and Pardis Niloo Cancer Center (2019-2021), specializing in 3D conformal radiotherapy, IMRT planning, machine QA, and dosimetry. She was also a Research Assistant (2012-2018) at Tehran University of Medical Sciences, collaborating on quantitative MRI and spectroscopy research. Dr. Beigi has significant experience in mentoring students, managing research projects, and implementing AI-driven radiotherapy solutions. Her work integrates imaging and machine learning to optimize treatment efficacy and minimize patient toxicity. 💼🔬

Research Interests 🔬

Dr. Manijeh Beigi’s research centers on dosimetry, radiotherapy quality audits, and the application of machine learning in radiomics and dosiomics. She explores AI-driven models to predict radiotherapy toxicity and optimize treatment planning. Her work integrates advanced MRI techniques, such as Diffusion Tensor Imaging (DTI), to enhance clinical target volume delineation for gliomas and other cancers. She investigates imaging biomarkers to assess radiation-induced damage and improve treatment precision. Additionally, Dr. Beigi is actively involved in multi-disciplinary research collaborations, utilizing deep learning for medical image analysis. Her contributions aim to advance radiation oncology by improving accuracy, reducing side effects, and personalizing treatment plans. 🧬📡

Dr. Manijeh Beigi has received several accolades for her contributions to medical physics and radiotherapy research. She has been recognized for her work in AI-driven radiomics and dosiomics at international conferences, including ESTRO and AAPM. Her research on glioma segmentation using DTI and radiotherapy toxicity prediction has been published in top-tier journals. She has also been awarded grants for her studies on advanced MRI applications in radiotherapy planning. Additionally, Dr. Beigi has played a key role in multi-institutional research collaborations, earning recognition for her leadership in medical imaging and quality assurance. 🏆🎖️

Publications 📚

Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

Posted on by sciencefather

Prof Dr.  Hongjun JIN | Nuclear Medicine Molecular Imaging | Interdisciplinary Innovation Prize

: Sun Yat-sen University Fifth Affiliated Hospital, china

Profile

Education

Dr. Hongjun Jin is a Principal Investigator in Nuclear Medicine and a Doctoral Supervisor of Molecular Medicine at Sun Yat-sen University. He earned his PhD in Biochemistry from Texas A&M University in 2007, following a BS in Radiochemistry from Lanzhou University in 1994 and a BMed in Chinese Medicine from Beijing University of Chinese Medicine in 1997. He completed his postdoctoral training at PNNL from 2008 to 2012 and served as a radiology instructor at Washington University in St. Louis from 2012 to 2017. Since 2017, he has led the PET and radiochemical laboratory at his institute, having been recruited through Sun Yat-sen University’s “Hundred Talents Program.”

Research and Innovations:

1) General Research Fund for National Sciences Foundation of China (NSFC), 82372004,
“F-18 labelled PET probe targeting P2X7 receptor for Evaluation of Treatment for AD”
01/01/2024-12/31/2027￥480,000,
2) Key R&D project, 0007/2022/AKP, Macao S&T Fund (FDCT),“R&D of an Integrated
Molecular probe for Targeted TNFR2 New Tumor Diagnosis and
Treatment”,01/01/2024-12/31/2027,￥2,400,000 (out of ￥120,000,000)
3) Guangdong Provincial Enterprise Joint Fund, 2021A1515220004, Guangdong Province
“PET/MRI Neuromolecular Imaging Quantitative Study of New Drug Targeting Sigma1

Research Project

  • 1) Outstanding Foreign Young Scientist Talent Program, RFIS, 82150610508 NSF-CN，
    “ Establishment and drug evaluation of acetylcholinergic and dopaminergic
    neuromolecular probes (18F VAT and 18F-DTBZ) PET brain imaging quantitative
    system for Parkinson’s disease” 2022/01-2022/12，￥400,000
  • General Research Fund for NSFC, 81871382, “F-18 labelled PET probe targeting P2X7
    receptor for early detection of AD”01/01/2019-12/31/2022￥570,000
  • SYSU “Hundred Talent “Starting Fund (Period I)” SYSU-FA10/01/2017-09/30/2022
    ￥2,500,000
  • National Key R&D Program for Precision Medicine, 2018YFC0910601 Real-time, highdimensional, multi-modality imaging co-registration and theronoastic strategies for
    oesophageal squamous-cell carcinomas10/01/2018-12/31/2020￥1,272,500 (out of
    ￥19,230,000)
  • Sun Yat-sen University Military Industry Cultivation Project, 89000-18843403 SYSU
    “Key Technologies of Molecular Imaging of Immune Dysfunction in Microgravity
    Environment”, 2019/08-2021/12￥1,890,00
  • Researchers Initiate Clinical Research Project (IIT) Award, SYSU-FAH”A single-center,
    open, prospective assessment of the diagnostic significance of 18F-FDG PET/CT
    dynamic imaging and gene sequencing in detecting metastatic lesions of non-small cell
    lung cancer”,2020/10-2021/09￥50,000
  • COVID-19 infection prevention and control emergency S&T, ZH22036302200036PWC,
    Zhuhai City”Specific Targeting S- protein of SARS-CoV-2 PET molecular imaging
    probe”2020/08-2021/09,￥70,000

Citation Index:

Google Scholar Citations: 8684 (total) 7943 (since 2020)
h-index 26(total) 20 (since 2020)
i10-index 52(total) 39(since 2020)

Publications